Today

Lynoo Pharmaceutical Packaging puts glass substrates first in Hong Kong listing plan

Jinan-based borosilicate glass maker Lynoo Pharmaceutical Packaging names industrialisation of glass substrates for semiconductor packaging, including a 4.8 million-piece-a-year line at its Jinan plant, as the main use of proceeds from the Hong Kong listing it applied for on 28 September 2026. Upgrades to its pharmaceutical glass business come second, and no fundraising target has been disclosed. Pharmaceutical glass revenue fell to USD 54m (CNY 357m) in 2025 from USD 70m (CNY 467m) in 2024.

Why this mattersA borosilicate pharmaceutical glass supplier is steering new capital to semiconductor substrates as its drug packaging revenue shrinks under Chinese healthcare cost controls and volume-based procurement.

  • Lynoo Pharmaceutical Packaging filed its Hong Kong listing application on 28 September 2026
  • Planned glass substrate line at the Jinan plant has 4.8 million pieces a year of capacity, covering melting, forming, cutting, grinding and polishing
  • A single large production furnace is estimated to cost USD 120m-150m (CNY 800m-1,000m)
  • Pharmaceutical glass packaging revenue fell to USD 54m (CNY 357m) in 2025, 36.3% of total revenue, from USD 70m (CNY 467m) in 2024
  • Household heat-resistant glass revenue rose to USD 91m (CNY 609m) in 2025, 62.1% of total revenue
  • The company renamed itself from Linuo Special Glass to Lynoo Pharmaceutical Packaging in November 2024
Lynoo Pharmaceutical Packaging
Relevant to you?

Written by AI from the sources above and checked by a second AI system before publication. No human wrote or edited this story. How it is made.

Updates

  • 2026-11-16 · Edited before publication: CNY revenue figures were not converted, and the furnace conversion was truncated rather than rounded (USD 120m-150m). USD now comes first. The filing dates from September and the company is shifting away from packaging, so materiality is lowered to 2.
  • 2026-11-16 · Edited before publication: The Hong Kong filing dates from 28 September; the 15 November article is a feature, so the headline should not present the filing as new. Why-it-matters restated facts rather than a consequence; rewritten using the source's explanation (healthcare cost control and volume-based procurement). Conversions correct.